Morning Industry Symposium: CDK4/6 inhibitors in advanced breast cancer: The future is now
Supported by Pfizer
pfizer oncology

Friday, October 12, 2018
07:00-08:30
Breakfast will be served prior to the session

 Chairperson TBA                                                                                                                                                                              Hall B
07:15 – 07:45 The science behind CDK4/6 inhibition
Javier Cortes, Spain
07:45 – 08:15
07:45
07:55
08:05
DEBATE: That all 1st line stage 4 ER+/HER2-patients should have a CDK4/6 inhibitor
Yes:  Rebecca Dent, Singapore
No:  Nick Murray, Australia
Discussion
08:15 – 08:30 Discussion